Clinical Trial Update: To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether continuing vemurafenib+cobimetinib with local treatment improves efficacy beyond progression versus second-line therapy in BRAF…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Intergruppo Melanoma Italiano | Conditions: Melanoma Metastatic, BRAF V600 Mutation | Phase 2 | Status: UNKNOWN